Postexposure prophylaxis for HIV infection

New England Journal of Medicine

Volumn 361, Issue 18, 2009, Pages 1768-

  Landovitz, Raphael J ^a   Currier, Judith S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANEMIA; ANUS INTERCOURSE; ARTICLE; ASTHENIA; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; JAUNDICE; LABORATORY TEST; NAUSEA; NEEDLESTICK INJURY; NEPHROLITHIASIS; NEPHROTOXICITY; NEUTROPENIA; OCCUPATIONAL ACCIDENT; OCCUPATIONAL EXPOSURE; OCCUPATIONAL SAFETY; ORAL SEXUAL CONTACT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SKIN DISEASE; TREATMENT DURATION; TREATMENT PLANNING; VIRUS TRANSMISSION; ADULT; DISEASE TRANSMISSION; DRUG COMBINATION; MALE; PRACTICE GUIDELINE; REVIEW; SEXUAL BEHAVIOR;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MALE; OCCUPATIONAL EXPOSURE; PRACTICE GUIDELINES AS TOPIC; SEXUAL BEHAVIOR;

EID: 84871079843     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp0904189     Document Type: Article

References (57)

1. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA 2008;300:520-529
2. Report on the global AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS, 2008. (Accessed October 2, 2009, at http://data.unaids. org/pub/GlobalReport/2008/JC1511-GR08-ExecutiveSummary-en.pdf.)
3. LaFon SW, Mooney BD, McMullen JP, et al. A double-blind, placebo-controlled study of the safety and efficacy of Retrovir (zidovudine, ZDV) as a chemoprophylactic agent in health care workers (HCW) exposed to HIV. In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, October 21-24, 1990. Atlanta: American Society for Microbiology, 1990:167.
4. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997;337:1485-1490 (Pubitemid 27495773)
5. Roland ME, Elbeik TA, Kahn JO, et al. HIV RNA testing in the context of nonoccupational postexposure prophylaxis. J Infect Dis 2004;190:598-604. (Pubitemid 38982101)
6. Ippolito G, Puro V, De Carli G. The risk of occupational human immunodeficiency virus infection in health care workers. Arch Intern Med 1993;153:1451-1458
7. Antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. Atlanta: Centers for Disease Control and Prevention, 2005.
8. Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 2008;8:553-563
9. Boily MC, Baggalaey RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009;9:118-129
10. Lifson AR, O'Malley PM, Hessol NA, Buchbinder SP, Cannon L, Rutherford GW. HIV seroconversion in two homosexual men after receptive oral intercourse with ejaculation: implications for counseling concerning safe sexual practices. Am J Public Health 1990;80:1509-1511
11. Rozenbaum W, Gharakhanian S, Cardon B, Duval E, Coulaud JP. HIV transmission by oral sex. Lancet 1988;1:1395.
12. Kaplan EH, Heimer R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Syndr Hum Retrovirol 1995;10:175-176
13. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. Atlanta: Centers for Disease Control and Prevention, September 30, 2005.
14. Offering HIV post-exposure prophylaxis (PEP) following non-occupational exposures: recommendations for health care providers in the state of California. Sacramento: California Task Force on Non-Occupational PEP, California Department of Health Services Office of AIDS, June 2004.
15. HIV prophylaxis following non-occupational exposure including sexual assault. Albany: New York State Department of AIDS Health Institute, 2004.
16. Nonoccupational HIV PEP Task Force, Brown University AIDS Program, Rhode Island Department of Health. Nonoccupational human immunodeficiency virus postexposure prophylaxis guidelines for Rhode Island healthcare practitioners. Providence: Brown University AIDS Program, Rhode Island Department of Health, 2002.
17. Post-exposure prophylaxis to prevent HIV infection: joint WHO/ILO guidelines on post-exposure prophylaxis (PEP) to prevent HIV infection. Geneva: World Health Organization, 2007.
18. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmeth-oxypropyl)adenine. Science 1995;270:1197-1199
19. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000;74:9771-9775
20. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-1414 (Pubitemid 28516063)
21. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998;72:4265-4273 (Pubitemid 28188732)
22. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739 (Pubitemid 27417972)
23. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indin avir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-1873
24. Lennox J, Dejesus E, Lazzarin A, et al. STARTMRK, a Phase III study of the safety and efficacy of raltegravir (RAL)-based vs efavirenz (EFV)-based combination therapy in treatment-naive HIV-infected patients. In: Program and abstracts of the 48th International Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 25-28, 2008. abstract.
25. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008;105:7552-7557
26. Puro V, De Carli G, Orchi N, et al. Short-term adverse effects from and discontinuation of antiretroviral post-exposure prophylaxis. J Biol Regul Homeost Agents 2001;15:238-242 (Pubitemid 32994572)
27. Bassett IV, Freedberg KA, Walensky RP. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis 2004;39:395-401.
28. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-260
29. Mayer KH, Mimiaga MJ, Cohen D, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston community health center. J Acquir Immune Defic Syndr 2008;47:494-499
30. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services, 2008. (Accessed October 2, 2009, at http://www.aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf.)
31. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep 2001;49:1153-1156
32. Patel SM, Johnson S, Belknap SM, Chan J, Sha BE, Bennett C. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr 2004;35:120-125 (Pubitemid 38133733)
33. Kahn JO, Martin JN, Roland ME, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis 2001;183:707-714 (Pubitemid 32171744)
34. Roland M, Neilands T, Krone M, et al. A randomized trial of standard versus enhanced risk reduction counseling for individuals receiving post-exposure prophylaxis following sexual exposures to HIV. In: Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections, Denver, February 5-8, 2006. abstract.
35. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30. (Pubitemid 30432540)
36. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. Atlanta: Centers for Disease Control and Prevention, June 29, 2001.
37. Browne R, Asboe D, Gilleece Y, et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men: is sexual transmission feeding the increase? Sex Transm Infect 2004;80:326-327
38. Ghosn J, Pierre-François S, Thibault V, et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med 2004;5:303-306 (Pubitemid 39077124)
39. Götz HM, van Doornum G, Niesters HG, den Hollander JG, Thio HB, de Zwart O. A cluster of acute hepatitis C virus infection among men who have sex with men - results from contact tracing and public health implications. AIDS 2005;19:969-974
40. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-264 (Pubitemid 43049856)
41. Gaines H, von Sydow M, Sönnerborg A, et al. Antibody response in primary human immunodeficiency virus infection. Lancet 1987;1:1249-1253 (Pubitemid 17070816)
42. Marlink RG, Allan JS, McLane MF, Essex M, Anderson KC, Groopman JE. Low sensitivity of ELISA testing in early HIV infection. N Engl J Med 1986;315:1549.
43. Branson BM. State of the art for diagnosis of HIV infection. Clin Infect Dis 2007;45:Suppl 4:S221-S225.
44. Ippolito G, Puro V, Heptonstall J, Jagger J, De Carli G, Petrosillo N. Occupational human immunodeficiency virus infection in health care workers: worldwide cases through September 1997. Clin Infect Dis 1999;28:365-383
45. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One 2007;2(9):e875.
46. Martin JN, Roland ME, Neilands TB, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004;18:787-792
47. Schechter M, do Lago RF, Mendelsohn AB, Moreira RL, Moulton LH, Harrison LH. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004;35:519-525
48. Shoptaw S, Rotheram-Fuller E, Landovitz R, et al. Non-occupational post exposure prophylaxis as a biobehavioral HIV-prevention intervention. AIDS Care 2008;20:376-381
49. Roland ME, Neilands TB, Krone MR, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005;41:1507-1513 (Pubitemid 41579997)
50. Prada N, Davis B, Jean-Pierre P, et al. Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course. J Acquir Immune Defic Syndr 2008;49:117-122
51. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28:1032-1035 (Pubitemid 29203534)
52. Méchai F, Quertainmont Y, Sahali S, Delfraissy JF, Ghosn J. Post-exposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a multi-resistant HIV-infected source person. J Med Virol 2008;80:9-10. (Pubitemid 350220083)
53. Siegel MO, Kan VL, Benator DA. Raltegravir for postexposure prophylaxis following occupational exposure to HIV. AIDS 2008;22:2552-2553
54. Mayer K, Mimiaga M, Gelman M, Trufant J, Maynard S, McMorrow P. Tenofovir DF/emtricitabine/raltegravir (TDF/FTC/RAL) appears well-tolerated for nonoccupational post-exposure prophylaxis. In: Proceedings of the 5th IAS Conference on HIV Pathogenesis, Treatment, and Prevention, Cape Town, South Africa, July 19-22, 2009. abstract.
55. Updated information regarding antiretroviral agents used as HIV postexposure prophylaxis for occupational HIV exposures. MMWR Morb Mortal Wkly Rep 2007;56:1291-1292
56. HIV prophylaxis following occupational exposure. Albany: New York State Department of Health AIDS Institute, 2008.
57. Bloodborne pathogens and needlestick prevention: post-exposure evaluation. Washington, DC: Occupational Safety & Health Administration, 2009. (Accessed October 2, 2009, at http://www.osha.gov/SLTC/ bloodbornepathogens/postexposure.html.)